Summary The effects of combretastatin A4 prodrug on perfusion and the levels of 31p metabolites in an implanted murine tumour were investigated for 3 h after drug treatment using nuclear magnetic resonance imaging (MRI) and spectroscopy (MRS). The area of regions of low signal intensity in spin-echo images of tumours increased slightly after treatment with the drug. These regions of low signal intensity corresponded to necrosis seen in histological sections, whereas the expanding regions surrounding them corresponded to haemorrhage. Tumour perfusion was assessed before and 160 min after drug treatment using dynamic MRI measurements of gadolinium diethylenetriaminepentaacetate (GdDTPA) uptake and washout. Perfusion decreased significantly in central regions of the tumour after treatment. This was attributed to disruption of the vasculature and was consistent with the haemorrhage seen in histological sections. The mean apparent diffusion coefficient of water within the tumour did not change, indicating that there was no expansion of necrotic regions during the 3 h after drug treatment. Localized 31P-MRS showed that there was decline in cellular energy status in the tumour after treatment with the drug. The concentrations of nucleoside triphosphates within the tumour fell, the inorganic phosphate concentration increased and there was a significant decrease in tumour pH for 80 min after drug treatment. The rapid, selective and extensive damage caused to these tumours by combretastatin A4 prodrug has highlighted the potential of the agent as a novel cancer chemotherapeutic agent. We have shown that the response of tumours to treatment with the drug may be monitored non-invasively using MRI and MRS experiments that are appropriate for use in a clinical setting.
Combretastatin A4 is a tubulin-binding compound originally isolated from Combretum caffrum, a Southern African shrub (Pettit et al, 1989) . Solubility in aqueous solutions is poor but is improved by conversion to disodium combretastatin A4 3-0-phosphate (combretastatin A4 prodrug) from which the phosphate group is cleaved by endogenous non-specific phosphatases under physiological conditions (Pettit et al, 1995) . The two compounds were shown to have similar activity against model murine, rat and human tumours (Dark et al, 1997) . The drug has been shown to have a direct and selective effect on tumour vasculature. In an isolated tumour model, infusion of the drug was shown to result in vascular shutdown within 20 min. Experiments in vitro have demonstrated that the drug has antiproliferative/cytotoxic effects against proliferating endothelial cells. However, it is thought unlikely that these effects of the drug on vascular endothelial cells could, on their own, explain the rapid disruption of tumour blood flow observed in vivo (Dark et al, 1997) . In contrast with colchicine and other tubulin-binding agents that have been investigated as agents for disrupting tumour vasculature, and for which dosage is limited by morbidity, combretastatin A4 prodrug is active at one-tenth of the maximum tolerated dose (Dark et al, 1997) .
The aim of this study was to determine whether changes in tumour perfusion caused by the drug could be monitored using clinically applicable magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) techniques. Perfusion can be measured quantitatively by dynamic monitoring of changes in signal intensity in spin-echo images of the tumour after introduction of a paramagnetic contrast-enhancing agent, GdDTPA. A variety of mathematical models have been used to analyse data of this type. Two relatively simple models were adopted in this study to describe the kinetics of uptake and clearance of GdDTPA. Both methods -analysis of the initial rate of inflow of GdDTPA, and the model of Kennedy et al (1994) -are sensitive to alterations in vascular integrity.
The apparent diffusion coefficient of water (ADC) measured by MRS (Stejskal and Tanner, 1965) and by MRI is affected by the physiological status of the tissue, in particular the compartmentalization of water (Latour et al, 1994) . Signal intensity in maps of tumour ADC have been shown to correlate with oxygen tension (Dunn et al, 1995) and with regions of necrosis (Maier et al, 1997) in model tumours. The vascular disruption that results from combretastatin A4 prodrug treatment (Dark et al, 1997) was expected to cause changes in oxygenation, and histological studies have demonstrated that tumours treated with the drug display haemorrhagic necrosis within 24 h. Tumour ADC maps were acquired in this study in order to determine whether such changes in tissue oxygenation and/or the onset of haemorrhagic necrosis could be detected by MRI.
Tumour perfusion can be monitored indirectly using 31P-MRS measurements of cellular energy status (Steen, 1989; Negendank, 1992; Tozer and Griffiths, 1992) . The technique reports on the levels of nucleoside triphosphates (NTP), phosphocreatine (PCr), inorganic phosphate (P) and other phosphorylated compounds, including phospholipid metabolites. The intracellular pH can also be determined from the chemical shift of the P, resonance (Hoult et al, 1974; Taylor et al, 1983; Stubbs et al, 1992) . The response of the tumour and underlying muscle tissue to drug treatment was investigated here in order to determine whether 31P-MRS might also provide a useful tool for monitoring the drug responsiveness of a tumour in the clinic.
MATERIALS AND METHODS Tumour model
The sarcoma F transplanted murine tumour model was used in this study. The tumours were initiated by injection of a tumour cell suspension (0.05 ml) dorsally into 12-to 16-week-old female CBA mice. Derivation and maintenance of this tumour model were as described in Denekamp et al (1983) . Experiments were conducted when tumours reached 7-9 mm geometric mean diameter (11-16 days after implantation). The tumours were subcutaneous masses that did not infiltrate the skin or underlying muscle tissue. Studies were conducted in accordance with the Animals (Scientific Procedures) Act 1986. Drug and anaesthetic preparation Anaesthesia was induced by intraperitoneal (i.p.) injection of Hypnorm/Hypnovel/dextrose saline in the ratio 5:4:31 (10 ml kg-' body weight). Hypnorm was from Jansen Pharmaceuticals and Hypnovel was from Roche. The dextrose-saline solution contained 4% dextrose and 0.18% saline. At the same time, dextrose saline (0.5 ml i.p.) was given to reduce animal dehydration. Anaesthesia was maintained with 1.75-hourly i.p. injections of Hypnorm-dextrose saline solution in the ratio 1:19 (5 ml kg-' body weight).
Combretastatin A4 prodrug, provided by GR Pettit (Arizona State University), was dissolved (10 mg ml-') in sterile saline (0.9% sodium chloride) and injected i.p. into mice at 100 mg kg-' body weight (Dark et al, 1997) . Before administration of combretastatin A4 prodrug, control images and spectra were obtained over a 2-h period, and were then acquired continuously for 3 h after drug treatment (n = 6 animals). Further controls (n = 6 animals) were used to assess the effect of vertical positioning of the animal for 5 h on blood flow and metabolic status of animal and tumour. The same experimental protocol was used as for the combretastatin-treated animals except that only the saline was administered. Gadolinium diethylenetriaminepentaacetate (GdDTPA) (Magnevist, Schering, diluted to 40 mm with sterile saline (0.9% sodium chloride)) was administered intravenously (i.v.) through a tail vein catheter over a period of 30 s, to give 200 gmol kg-' body weight (compared with 100 ,umol kg-' used in clinical MRI).
Magnetic resonance imaging and spectroscopy
Experiments were performed in a 9.4-T vertical-bore (8.9 cm diameter) superconducting magnet (Oxford), interfaced with a Varian Associates UnityPlus console and Sun workstation running VNMR 5.3B. An unshielded gradient set (Varian Associates) was used with a probe incorporating a two-tum surface coil (20-mmdiameter) tunable to frequencies of 400 MHz ('H-imaging) and 162 MHz (3'P-spectroscopy). Animals were immobilized in a cradle that held the tumour in the centre of the surface coil. A flow of warm air was used to maintain the body temperature of the animals. 31p spectra, PI/NTP ratios and pH measurements Localized 3p spectra of the tumour and underlying muscle tissue were obtained using image-selected in vivo spectroscopy [ISIS (Ordidge et al, 1986) ] before and at three time points after combretastatin A4 was administered. Typically, 16 x 8 summed free induction decays, acquired into 11 968 data points over 0.4 s, were collected from voxels of dimensions 6 x 15 x 15 mm. A relaxation delay of 2 s was used in order to minimize the time required for signal acquisition. A Lorentz-Gauss transformation was applied to the summed free induction decay before Fourier transformation to enhance resolution. Spectra were referenced to the resonance of phosphocreatine at 0.0 p.p.m. The frequencies of the excitation pulses were set at the phosphocreatine resonance frequency. No corrections were made for resonance offset effects or the effects of incomplete relaxation. The absence of a discemible phosphocreatine signal in the localized spectra of the tumours indicated that there was negligible contamination of the signals from tumour metabolites with signals from metabolites in the underlying muscle tissue. Areas under peaks were integrated for calculation of inorganic phosphate to total NTP ratios (P,/NTP ratios).
Tumour pH was calculated from the chemical shift of the inorganic phosphate (Pt) resonance according to equation 1 (Taylor et al, 1983; Gillies et al, 1991): 6 -0.77 pH= pKa+log 3.16-
where pKa is 6.85 and 6 is the measured chemical shift of P. in p.p.m relative to that of 85% phosphoric acid. For pH calculations, the observed frequency of the a-phosphate of NTP was assumed to be at -10.05 p.p.m. from the orthophosphate resonance (Gillies et al, 1991) .
Tumour perfusion
GdDTPA was introduced as a bolus via a tail vein catheter and inflow into the tumour was monitored with a series of T,-weighted spin-echo images (TE = 21.5 ms, TR = 130 ms), which were collected for 10 min after injection (Kennedy et al, 1994) . The images were acquired from a 2-mm-thick slice and the field of view was 20 mm over a 512 x 128 (phase encode) matrix, which was zero filled to 512 x 256. At 10 min after injection, an image was collected with TR = 3 s and the image pixel intensities in the short TR experiments were converted to RIP values (RIP is the paramagnetic contribution to the longitudinal relaxation rate and is proportional to the concentration of the contrast agent) using the expression derived by Kennedy et al (1994) . The kinetics of inflow and outflow were then modelled according to equation 2 (Kennedy et al, 1994) : 
where y is the gyromagnetic ratio (for 'H, y = 26.75 x 107 T-' s-1), 6 is the diffusion gradient duration, A is the time between the diffusion gradients, G is the diffusion gradient strength and D is the diffusion coefficient for the observed species (Stejskal and Tanner, 1965) . The images were acquired with TE = 37 ms, TR = 1.5 s, A = 14 ms, and 6 = 10 ms, to give b values ranging from 7. Figure 3A and B (the data were taken from the regions shown in Figure 2A ). An increase in the time constant for
GdDTPA uptake (TU) was observed in the tumour centre after drug 0 100 200 300 400 500 600 700 treatment ( Figure 3 and Table 1 ). This was seen in central regions
where the initial-rate analysis had indicated a reduction in perfusion [ (Figure 2A(m) ], and also in central regions which did not 'inetic analysis of perfusion of sarcoma F tumour and its response exhibit a marked change in initial rate of signal enhancement astatin A4 prodrug. Three regions of the tumour image in Figure 2A [ (Figure 2A(n) ]. An increase in Tu for tumour periphery [ Figure   used to illustrate the differences in kinetics before and after 2A(o)] after drug treatment was also seen, but this was not signifiion of the drug. Curves of best fit satisfying equation 2 are (A) bretastatin A4 prodrug treatment and (B) 160 min after treatment. cantly different from control values (Table 1 ). In the peripheral ignificant change is the reduction in inflow kinetics after regions the maximal concentration of GdDTPA increased after ion of the drug. An increase in Tu was seen for regions which combretastatin A4 prodrug treatment ( Figure 3B ). The calculated arge decrease in initial rate of signal enhancement after atin A treatment (for example (m) in Figure 2A ) and for regions in values of Tc are not quoted in Table 1 as they were of the order of iitial-rate analysis did not show a marked change [regions (n) and 2000 s and therefore were not well determined by the inflow e 2A] (see Table 1) measurements, which were made over a period of 600 s. The apparent diffusion coefficient of tumour water (ADC) was determined at up to 1.8 h after treatment with combretastatin A4
prodrug. The ADC maps (not shown) generated from these data showed no significant changes in the mean ADC of tumour water during this period. The mean tumour ADC (n = 6) in the plane observed was 0.7 ± 0.1 x li9 m2 s-1 before treatment, 0.8±0.1 x 10-9m2s -at0.8h,and0.8±0.3x 10-9m2s-at 1.8h after treatment (errors are 1 s.d.). The mean ADCs in necrotic regions, 1.3 ± 0.2 x 109 m2 s-1, and in viable tissue, 0.7 ± 0.1 x 1J9 m2 s-1were similar to the values found by Maier et al (1997) in model breast tumours.
No changes in the levels of NMR-visible phosphorus metabolites in muscle tissue were observed during the 2.5 h after administration of the drug ( Figure 4B ). However, localized spectra from the tumour indicated a decline in cellular energy status. The signals due to a-, f-and y-phosphates of NTP in the tumour decreased in intensity ( Figure 4A ), whereas the signal due to P1 increased in intensity. The phosphomonoester peak, which in many tumours is composed mainly of the resonances from phosphocholine and phosphoethanolamine (Bhujwalla et al, 1994) , exhibited no significant change in intensity. The ratio of PJ/NTP in these ISIS-localized spectra rose from 0.4 ± 0.1 to 0.8 ± 0.1 (n = 6, errors are 1 s.d.) during the 2.5 h after administration of combretastatin A4 prodrug ( Figure 4C ). The pH in the tumour decreased from 7.0 ± 0.1 before treatment to a minimum of 6.82 ± 0.03 (n = 6) after 30 min (errors are 1 s.d.) ( Figure 4D ). After this time the response of the tumours was variable. This was reflected in an increase in the standard deviation of mean tumour pH, which had a value of 6.9 ± 0.2 at 150 min.
Control experiments (n = 6) indicated that vertical positioning of the animal in the magnet for up to 5 h had no effect on tumour perfusion, as determined from GdDTPA inflow measurements (see Table 1 ), or from the pH or levels of NMR-visible phosphoruscontaining metabolites in the tumours ( Figure 4C and D) or underlying muscle tissue (data not shown).
DISCUSSION
Combretastatin A4 and its soluble phosphate prodrug have been shown previously to cause rapid and selective disruption of tumour vasculature (Chaplin et al, 1996; Dark et al, 1997) . The results of Table 1 Time constants for uptake (Tu) of GdDTPA for tumour centre (pixels more than c. 1.5 mm from tumour edge) and periphery (pixels less than c. 1.5 mm from tumour edge) in response to treatment with combretastatin A4 the vascular disruption induced by the drug are shown here to be evident in MRI and MRS experiments on an implanted murine tumour model. The low signal intensity in moderately T2-weighted spin-echo images of the tumours ( Figure IA ) correlated with regions of necrosis seen in histological sections of tumours, which contained extravasated erythrocytes (data not shown). After treatment with the drug the regions of low signal intensity expanded slightly (Figure iB) and this expansion correlated with haemorrhage observed in histological sections taken at the end of the MRI experiment ( Figure IC) . The low signal intensity, which was also observed in the images acquired with a longer relaxation delay (TR = 3 s), is attributed to the presence of paramagnetic deoxygenated haemoglobin in these regions (Brooks and Di Chiro, 1987) . This enhances the spin-spin (T2) relaxation of water protons and thus reduces their signal intensity in the spin-echo images.
The perfusion characteristics of the tumour underwent significant changes after drug treatment. An initial-rate analysis of GdDTPA inflow data (Figure 2 ) demonstrated that the alteration to the perfusion characteristics was not uniform across the tumour. In general, the sarcoma F tumour contains both well-perfused (high signal intensity in Figure 2 ) and poorly perfused regions (low signal intensity). After treatment with combretastatin A4 prodrug, the initial rate of GdDTPA inflow was reduced in some or all of the central regions with relatively high perfusion (Figure 2 ), whereas the extent of GdDTPA perfusion was increased in peripheral regions of the tumour.
The model of Kennedy et al (1994) was used to analyse regions that had differing characteristics in the initial rate maps. The uptake and clearance of the paramagnetic relaxation agent GdDTPA are described in terms of the time constants for uptake (TU) and clearance (TC), each of which is assumed to follow firstorder kinetics. The uptake and clearance of the agent are dependent on the perfusion characteristics of the tissue, and were found to alter after combretastatin A treatment.
Tu and Tc were calculated for specific regions of the tumours before and 160 min after administration of combretastatin A4. Before treatment, there was a rapid inflow of the agent into the tissue via the tumour vasculature, followed by a slow clearance resulting from removal of the tracer from the blood stream ( Figure   3A ). After treatment with the drug the time constant for uptake (TU) was greatly increased ( Figure 3B , Table 1 ). This analysis was more sensitive to reductions in tracer inflow than the initial rate analysis and showed that Tu was increased in regions of the tumour that did not exhibit a significant reduction in the initial rate of contrast agent uptake, as illustrated in Figure 3B . These data showed that druginduced damage to the vasculature resulted in a significant decrease in the rate of perfusion of the tumour centre (Table 1 ). The analysis also confirmed the apparent increase in extent of perfusion of the tumour periphery, which was observed in the initial rate maps after drug treatment. Figure 3 shows that the concentration of the contrast agent was increased in the tumour periphery after treatment with the drug, implying that disruption of the vasculature at the centre of the tumour had diverted blood flow to the periphery. This phenomenon of increased peripheral perfusion may be exploitable in enhancing the delivery of a co-administered chemotherapeutic agent targeted at viable tumour cells in peripheral regions of the tumour.
The energy status of the tumour also responded to drug treatment. 31P-MR spectra were obtained from voxels containing tumour tissue (tumour volume approximately 300 mm3) ( Figure  4A ) and underlying muscle (1350 mm3) ( Figure 4B ) for up to 2.7 h PME Pi 
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Cancer Research Campaign 1998 2 after administration of the drug. No perturbation in the metabolism of the underlying muscle was observed, but there was a steady decrease in the energetic status of the tumour, as indicated by an increasing P. /NTP ratio ( Figure 4C ). The P. in these tumours is assumed to be mainly intracellular (Stubbs et al, 1992 ). An initial decrease in tumour pH was seen at 30 min after drug treatment in all tumours. The pH response of the tumours after this period varied but, on average, remained more acidic than before treatment ( Figure 4D ). The decline in cellular energy status is presumably the result of the decreased perfusion observed in the MRI experiments . The decrease in pH was assumed to be due to increased lactate concentrations, resulting from decreased oxygenation of the tumours (Steen, 1989) . Diffusion-weighted MRI has demonstrated potential for providing information on tumour oxygenation (Dunn et al, 1995) and necrosis (Maier et al, 1997) . Decreased oxygenation has been shown to decrease the ADC of tumour water (Dunn et al, 1995) and necrosis has been shown to increase it (Maier et al, 1997) . However there was no significant change in ADC maps acquired before and for up to 1.8 h after treatment with combretastatin A4
prodrug. This may reflect the fact that there was no change in the cellularity of the tumours in these regions (as shown by histology, Figure IC) , whereas in the necrotic regions of two model breast tumours (Maier et al, 1997) , in which the water ADC was increased, there was a decrease in cellularity. The reason why there was no decrease in water ADC, despite the fact that the oxygenation of the tumours must almost certainly have been decreased after drug treatment, is not clear.
In conclusion, combretastatin A4 prodrug caused damage to the vasculature of a murine tumour model that resulted in haemorrhage, reduction in tumour perfusion rates, and decreased tumour energy status that could be detected using MRI and MRS experiments. The magnetic field strength and therefore sensitivity of the MR spectrometer used in this study was greater than those used clinically. Nevertheless we believe these techniques, in particular the GdDTPA inflow experiment, could be used in the clinic to determine the response of human tumours to treatment with this drug.
